{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:41:21Z","timestamp":1790700081529,"version":"4.1.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41582-026-01232-9","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:09:22Z","timestamp":1781870962000},"page":"519-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Narcolepsy is (not) an autoimmune disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-5620","authenticated-orcid":false,"given":"Anne","family":"Vassalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-3914","authenticated-orcid":false,"given":"Mehdi","family":"Tafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5477-5475","authenticated-orcid":false,"given":"Roland S.","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti, C. L. A. et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat. Rev. Neurol. 15, 519\u2013539 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997 (2000).","journal-title":"Nat. Med."},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5665\/sleep.3300","volume":"37","author":"M Tafti","year":"2014","unstructured":"Tafti, M. et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 37, 19\u201325 (2014).","journal-title":"Sleep"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41577-023-00902-9","volume":"24","author":"RS Liblau","year":"2024","unstructured":"Liblau, R. S., Latorre, D., Kornum, B. R., Dauvilliers, Y. & Mignot, E. J. The immunopathogenesis of narcolepsy type 1. Nat. Rev. Immunol. 24, 33\u201348 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1232_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa055","volume":"43","author":"BR Kornum","year":"2020","unstructured":"Kornum, B. R. Narcolepsy type 1: what have we learned from immunology? Sleep 43, zsaa055 (2020).","journal-title":"Sleep"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.1957.02980130015004","volume":"164","author":"E Witebsky","year":"1957","unstructured":"Witebsky, E., Rose, N. R., Terplan, K., Paine, J. R. & Egan, R. W. Chronic thyroiditis and autoimmunization. J. Am. Med. Assoc. 164, 1439\u20131447 (1957).","journal-title":"J. Am. Med. Assoc."},{"key":"1232_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","volume":"14","author":"NR Rose","year":"1993","unstructured":"Rose, N. R. & Bona, C. Defining criteria for autoimmune diseases (Witebsky\u2019s postulates revisited). Immunol. Today 14, 426\u2013430 (1993).","journal-title":"Immunol. Today"},{"key":"1232_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220911120","volume":"120","author":"A Seifinejad","year":"2023","unstructured":"Seifinejad, A. et al. Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy. Proc. Natl Acad. Sci. USA 120, e2220911120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322\u2013327 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573\u2013585 (1998).","journal-title":"Cell"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bph.12324","volume":"171","author":"JP Kukkonen","year":"2014","unstructured":"Kukkonen, J. P. & Leonard, C. S. Orexin\/hypocretin receptor signalling cascades. Br. J. Pharmacol. 171, 314\u2013331 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"1232_CR12","doi-asserted-by":"publisher","unstructured":"Tzanoulinou, S. et al. Divergent modulation of dopaminergic neurons by hypocretin\/orexin receptors-1 and-2 shapes dopaminergic cell activity and socio-emotional behavior. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.02.14.638329 (2025).","DOI":"10.1101\/2025.02.14.638329"},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39\u201340 (2000).","journal-title":"Lancet"},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553\u20131562 (2002).","journal-title":"Arch. Neurol."},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1399-0039.1998.tb02952.x","volume":"51","author":"Z Pelin","year":"1998","unstructured":"Pelin, Z., Guilleminault, C., Risch, N., Grumet, F. C. & Mignot, E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US modafinil in narcolepsy multicenter study group. Tissue Antigens 51, 96\u2013100 (1998).","journal-title":"Tissue Antigens"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","volume":"30","author":"J Hara","year":"2001","unstructured":"Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345\u2013354 (2001).","journal-title":"Neuron"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","volume":"34","author":"S Tabuchi","year":"2014","unstructured":"Tabuchi, S. et al. Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 34, 6495\u20136509 (2014).","journal-title":"J. Neurosci."},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.26300","volume":"91","author":"L Shan","year":"2022","unstructured":"Shan, L., Balesar, R., Swaab, D. F., Lammers, G. J. & Fronczek, R. Reduced numbers of corticotropin-releasing hormone neurons in narcolepsy type 1. Ann. Neurol. 91, 282\u2013288 (2022).","journal-title":"Ann. Neurol."},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000514964","volume":"45","author":"D Sagi","year":"2021","unstructured":"Sagi, D., de Lecea, L. & Appelbaum, L. Heterogeneity of hypocretin\/orexin neurons. Front. Neurol. Neurosci. 45, 61\u201374 (2021).","journal-title":"Front. Neurol. Neurosci."},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"RC168","DOI":"10.1523\/JNEUROSCI.21-19-j0003.2001","volume":"21","author":"TC Chou","year":"2001","unstructured":"Chou, T. C. et al. Orexin (hypocretin) neurons contain dynorphin. J. Neurosci. 21, RC168 (2001).","journal-title":"J. Neurosci."},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1046\/j.1471-4159.2002.01141.x","volume":"82","author":"IM Reti","year":"2002","unstructured":"Reti, I. M., Reddy, R., Worley, P. F. & Baraban, J. M. Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J. Neurochem. 82, 1561\u20131565 (2002).","journal-title":"J. Neurochem."},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1212\/01.WNL.0000168173.71940.ab","volume":"65","author":"A Crocker","year":"2005","unstructured":"Crocker, A. et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65, 1184\u20131188 (2005).","journal-title":"Neurology"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1212\/01.wnl.0000175219.01544.c8","volume":"65","author":"AM Blouin","year":"2005","unstructured":"Blouin, A. M. et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65, 1189\u20131192 (2005).","journal-title":"Neurology"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5665\/sleep.5532","volume":"39","author":"M Tafti","year":"2016","unstructured":"Tafti, M. et al. Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep 39, 581\u2013587 (2016).","journal-title":"Sleep"},{"key":"1232_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36120-z","volume":"14","author":"HM Ollila","year":"2023","unstructured":"Ollila, H. M. et al. Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. Nat. Commun. 14, 2709 (2023).","journal-title":"Nat. Commun."},{"key":"1232_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001164","volume":"8","author":"Y Natori","year":"2020","unstructured":"Natori, Y. et al. Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab. J. Immunother. Cancer 8, e001164 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1232_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","volume":"38","author":"TO Sarkanen","year":"2018","unstructured":"Sarkanen, T. O., Alakuijala, A. P. E., Dauvilliers, Y. A. & Partinen, M. M. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med. Rev. 38, 177\u2013186 (2018).","journal-title":"Sleep Med. Rev."},{"key":"1232_CR29","doi-asserted-by":"publisher","first-page":"902840","DOI":"10.3389\/fimmu.2022.902840","volume":"13","author":"SM Buonocore","year":"2022","unstructured":"Buonocore, S. M. & van der Most, R. G. Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Front. Immunol. 13, 902840 (2022).","journal-title":"Front. Immunol."},{"key":"1232_CR30","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/brain\/awab455","volume":"145","author":"R Bernard-Valnet","year":"2022","unstructured":"Bernard-Valnet, R. et al. Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. Brain 145, 2018\u20132030 (2022).","journal-title":"Brain"},{"key":"1232_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae014","volume":"47","author":"N Pagh-Berendtsen","year":"2024","unstructured":"Pagh-Berendtsen, N. et al. Downregulation of hypocretin\/orexin after H1N1 Pandemrix vaccination of adolescent mice. Sleep 47, zsae014 (2024).","journal-title":"Sleep"},{"key":"1232_CR32","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","volume":"37","author":"C Cohet","year":"2019","unstructured":"Cohet, C. et al. Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine 37, 3006\u20133021 (2019).","journal-title":"Vaccine"},{"key":"1232_CR33","doi-asserted-by":"publisher","first-page":"zsac325","DOI":"10.1093\/sleep\/zsac325","volume":"46","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: a nationwide narcolepsy surveillance network study in mainland China, 1990-2017. Sleep 46, zsac325 (2023).","journal-title":"Sleep"},{"key":"1232_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/sleep\/32.8.979","volume":"32","author":"A Aran","year":"2009","unstructured":"Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979\u2013983 (2009).","journal-title":"Sleep"},{"key":"1232_CR35","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ana.22587","volume":"70","author":"F Han","year":"2011","unstructured":"Han, F. et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70, 410\u2013417 (2011).","journal-title":"Ann. Neurol."},{"key":"1232_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.sleep.2020.03.019","volume":"72","author":"Q Ding","year":"2020","unstructured":"Ding, Q. et al. Anti-streptococcal antibodies in Chinese patients with type -1 narcolepsy. Sleep Med. 72, 37\u201340 (2020).","journal-title":"Sleep Med."},{"key":"1232_CR37","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1084\/jem.20160897","volume":"213","author":"FJ Hartmann","year":"2016","unstructured":"Hartmann, F. J. et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J. Exp. Med. 213, 2621\u20132633 (2016).","journal-title":"J. Exp. Med."},{"key":"1232_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169836","volume":"12","author":"M Lecendreux","year":"2017","unstructured":"Lecendreux, M. et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory T cells and with a systemic activation of global T cells. PLoS ONE 12, e0169836 (2017).","journal-title":"PLoS ONE"},{"key":"1232_CR39","doi-asserted-by":"publisher","first-page":"155103","DOI":"10.1016\/j.cyto.2020.155103","volume":"131","author":"S Mohammadi","year":"2020","unstructured":"Mohammadi, S., Mayeli, M., Saghazadeh, A. & Rezaei, N. Cytokines in narcolepsy: a systematic review and meta-analysis. Cytokine 131, 155103 (2020).","journal-title":"Cytokine"},{"key":"1232_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.sleep.2021.07.024","volume":"85","author":"R Viste","year":"2021","unstructured":"Viste, R. et al. Narcolepsy type 1 patients have lower levels of effector memory CD4+ T cells compared to their siblings when controlling for H1N1-(Pandemrix\u2122)-vaccination and HLA DQB1*06:02 status. Sleep Med. 85, 271\u2013279 (2021).","journal-title":"Sleep Med."},{"key":"1232_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249405","volume":"14","author":"L Khajavi","year":"2023","unstructured":"Khajavi, L. et al. The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I. Front. Immunol. 14, 1249405 (2023).","journal-title":"Front. Immunol."},{"key":"1232_CR42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bbi.2013.12.019","volume":"37","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers, Y. et al. Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study. Brain Behav. Immun. 37, 260\u2013266 (2014).","journal-title":"Brain Behav. Immun."},{"key":"1232_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf125","volume":"7","author":"M Moresco","year":"2025","unstructured":"Moresco, M. et al. Elevated circulating cell-free mitochondrial DNA level in cerebrospinal fluid of narcolepsy type 1. Brain Commun. 7, fcaf125 (2025).","journal-title":"Brain Commun."},{"key":"1232_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbi.2015.03.004","volume":"49","author":"BR Kornum","year":"2015","unstructured":"Kornum, B. R. et al. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav. Immun. 49, 54\u201358 (2015).","journal-title":"Brain Behav. Immun."},{"key":"1232_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaut.2015.03.003","volume":"60","author":"M Lecendreux","year":"2015","unstructured":"Lecendreux, M. et al. Impact of cytokine in type 1 narcolepsy: role of pandemic H1N1 vaccination? J. Autoimmun. 60, 20\u201331 (2015).","journal-title":"J. Autoimmun."},{"key":"1232_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1108682","volume":"14","author":"I Ayoub","year":"2023","unstructured":"Ayoub, I. et al. Cerebrospinal fluid proteomics in recent-onset narcolepsy type 1 reveals activation of the complement system. Front. Immunol. 14, 1108682 (2023).","journal-title":"Front. Immunol."},{"key":"1232_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103234","volume":"146","author":"A Huth","year":"2024","unstructured":"Huth, A. et al. Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy. J. Autoimmun. 146, 103234 (2024).","journal-title":"J. Autoimmun."},{"key":"1232_CR48","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ana.78199","volume":"99","author":"L Shan","year":"2026","unstructured":"Shan, L. et al. Increased numbers of CD4+ T-cells in the hypocretin\/orexin region of narcolepsy type 1. Ann. Neurol. 99, 1173\u20131178 (2026).","journal-title":"Ann. Neurol."},{"key":"1232_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp8109","volume":"17","author":"A Pignata","year":"2025","unstructured":"Pignata, A. et al. Tissue-resident memory CD4+ T cells infiltrate the CNS in progressive multiple sclerosis and contribute to chronic autoimmunity in mice. Sci. Transl. Med. 17, eadp8109 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1232_CR50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1399-0039.1984.tb00031.x","volume":"23","author":"J Seignalet","year":"1984","unstructured":"Seignalet, J. & Billiard, M. Possible association between HLA-B7 and narcolepsy. Tissue Antigens 23, 188\u2013189 (1984).","journal-title":"Tissue Antigens"},{"key":"1232_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1399-0039.1984.tb02144.x","volume":"24","author":"T Juji","year":"1984","unstructured":"Juji, T., Satake, M., Honda, Y. & Doi, Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24, 316\u2013319 (1984).","journal-title":"Tissue Antigens"},{"key":"1232_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-981-99-9781-7_16","volume":"1444","author":"T Shiina","year":"2024","unstructured":"Shiina, T. & Kulski, J. K. HLA genetics for the human diseases. Adv. Exp. Med. Biol. 1444, 237\u2013258 (2024).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1232_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","volume":"562","author":"D Latorre","year":"2018","unstructured":"Latorre, D. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562, 63\u201368 (2018).","journal-title":"Nature"},{"key":"1232_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/d41586-018-06666-w","volume":"562","author":"RS Liblau","year":"2018","unstructured":"Liblau, R. S. Put to sleep by immune cells. Nature 562, 46\u201348 (2018).","journal-title":"Nature"},{"key":"1232_CR55","doi-asserted-by":"publisher","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","volume":"115","author":"G Luo","year":"2018","unstructured":"Luo, G. et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc. Natl Acad. Sci. USA 115, E12323\u2013E12332 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22637-8","volume":"12","author":"A Vuorela","year":"2021","unstructured":"Vuorela, A. et al. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat. Commun. 12, 2283 (2021).","journal-title":"Nat. Commun."},{"key":"1232_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87481-8","volume":"11","author":"G Luo","year":"2021","unstructured":"Luo, G., Yogeshwar, S., Lin, L. & Mignot, E. J. T cell reactivity to regulatory factor X4 in type 1 narcolepsy. Sci. Rep. 11, 7841 (2021).","journal-title":"Sci. Rep."},{"key":"1232_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08774-1","volume":"10","author":"NW Pedersen","year":"2019","unstructured":"Pedersen, N. W. et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat. Commun. 10, 837 (2019).","journal-title":"Nat. Commun."},{"key":"1232_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuron.2024.12.006","volume":"113","author":"Y Segal","year":"2025","unstructured":"Segal, Y. et al. Toward curing neurological autoimmune disorders: biomarkers, immunological mechanisms, and therapeutic targets. Neuron 113, 345\u2013379 (2025).","journal-title":"Neuron"},{"key":"1232_CR60","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41591-019-0403-9","volume":"25","author":"A Christophersen","year":"2019","unstructured":"Christophersen, A. et al. Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions. Nat. Med. 25, 734\u2013737 (2019).","journal-title":"Nat. Med."},{"key":"1232_CR61","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","volume":"57","author":"C Saggau","year":"2024","unstructured":"Saggau, C. et al. Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity 57, 2416\u20132432.e2418 (2024).","journal-title":"Immunity"},{"key":"1232_CR62","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41592-021-01201-8","volume":"18","author":"JA Pai","year":"2021","unstructured":"Pai, J. A. & Satpathy, A. T. High-throughput and single-cell T cell receptor sequencing technologies. Nat. Methods 18, 881\u2013892 (2021).","journal-title":"Nat. Methods"},{"key":"1232_CR63","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41590-025-02412-3","volume":"27","author":"F Hayashi","year":"2026","unstructured":"Hayashi, F. et al. Antigen specificity of clonally enriched CD8+ T cells in multiple sclerosis. Nat. Immunol. 27, 490\u2013502 (2026).","journal-title":"Nat. Immunol."},{"key":"1232_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymeth.2026.02.004","volume":"248","author":"E Mertens","year":"2026","unstructured":"Mertens, E., Willekens, B., Derdelinckx, J. & Cools, N. Novel methods for the discovery of disease-associated T cell epitopes in autoimmunity. Methods 248, 64\u201382 (2026).","journal-title":"Methods"},{"key":"1232_CR65","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474 (2000).","journal-title":"Neuron"},{"key":"1232_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac052","volume":"45","author":"AE van der Hoeven","year":"2022","unstructured":"van der Hoeven, A. E. et al. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. Sleep 45, zsac052 (2022).","journal-title":"Sleep"},{"key":"1232_CR67","doi-asserted-by":"publisher","first-page":"106505","DOI":"10.1016\/j.sleep.2025.106505","volume":"131","author":"JP Kukkonen","year":"2025","unstructured":"Kukkonen, J. P., Turunen, P. M. & Rinne, M. K. Detection of reduced orexin-A\/hypocretin-1 and its fragments by orexin-A \u201cgold-standard\u201d radioimmunoassay. Sleep Med. 131, 106505 (2025).","journal-title":"Sleep Med."},{"key":"1232_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf237","volume":"48","author":"J Vialaret","year":"2025","unstructured":"Vialaret, J. et al. 16-mer hypocretin-1\/orexin-A in cerebrospinal fluid to diagnose narcolepsy. Sleep 48, zsaf237 (2025).","journal-title":"Sleep"},{"key":"1232_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1172\/JCI41366","volume":"120","author":"V Cvetkovic-Lopes","year":"2010","unstructured":"Cvetkovic-Lopes, V. et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713\u2013719 (2010).","journal-title":"J. Clin. Invest."},{"key":"1232_CR70","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/sleep\/33.7.875","volume":"33","author":"H Toyoda","year":"2010","unstructured":"Toyoda, H. et al. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 33, 875\u2013878 (2010).","journal-title":"Sleep"},{"key":"1232_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/sleep\/33.7.869","volume":"33","author":"M Kawashima","year":"2010","unstructured":"Kawashima, M. et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 33, 869\u2013874 (2010).","journal-title":"Sleep"},{"key":"1232_CR72","doi-asserted-by":"publisher","first-page":"17061","DOI":"10.1073\/pnas.1902148116","volume":"116","author":"A Seifinejad","year":"2019","unstructured":"Seifinejad, A. et al. Molecular codes and in vitro generation of hypocretin and melanin concentrating hormone neurons. Proc. Natl Acad. Sci. USA 116, 17061\u201317070 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR73","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/sleep\/29.10.1339","volume":"29","author":"CR Baumann","year":"2006","unstructured":"Baumann, C. R. et al. Sleep EEG changes after middle cerebral artery infarcts in mice: different effects of striatal and cortical lesions. Sleep 29, 1339\u20131344 (2006).","journal-title":"Sleep"},{"key":"1232_CR74","doi-asserted-by":"publisher","first-page":"855","DOI":"10.5665\/sleep.5642","volume":"39","author":"JY Wang","year":"2016","unstructured":"Wang, J. Y. et al. Cerebrospinal fluid orexin A levels and autonomic function in Kleine-Levin syndrome. Sleep 39, 855\u2013860 (2016).","journal-title":"Sleep"},{"key":"1232_CR75","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181bd1344","volume":"73","author":"Y Dauvilliers","year":"2009","unstructured":"Dauvilliers, Y., Abril, B., Mas, E., Michel, F. & Tafti, M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 73, 1333\u20131334 (2009).","journal-title":"Neurology"},{"key":"1232_CR76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.sleep.2022.10.004","volume":"101","author":"EW Torstensen","year":"2023","unstructured":"Torstensen, E. W. et al. Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls. Sleep Med. 101, 213\u2013220 (2023).","journal-title":"Sleep Med."},{"key":"1232_CR77","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0896-6273(03)00331-3","volume":"38","author":"A Yamanaka","year":"2003","unstructured":"Yamanaka, A. et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38, 701\u2013713 (2003).","journal-title":"Neuron"},{"key":"1232_CR78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/atm.ATM_181_17","volume":"13","author":"AS Almeneessier","year":"2018","unstructured":"Almeneessier, A. S. et al. The effects of diurnal intermittent fasting on the wake-promoting neurotransmitter orexin-A. Ann. Thorac. Med. 13, 48\u201354 (2018).","journal-title":"Ann. Thorac. Med."},{"key":"1232_CR79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuroscience.2022.04.006","volume":"491","author":"V Linehan","year":"2022","unstructured":"Linehan, V. & Hirasawa, M. Short-term fasting induces alternate activation of orexin and melanin-concentrating hormone neurons in rats. Neuroscience 491, 156\u2013165 (2022).","journal-title":"Neuroscience"},{"key":"1232_CR80","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1210\/en.2003-0274","volume":"144","author":"S Diano","year":"2003","unstructured":"Diano, S., Horvath, B., Urbanski, H. F., Sotonyi, P. & Horvath, T. L. Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets. Endocrinology 144, 3774\u20133778 (2003).","journal-title":"Endocrinology"},{"key":"1232_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4953","volume":"10","author":"TC Thannickal","year":"2018","unstructured":"Thannickal, T. C. et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci. Transl. Med. 10, eaao4953 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1232_CR82","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.biopsych.2018.07.022","volume":"85","author":"MH James","year":"2019","unstructured":"James, M. H. et al. Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats. Biol. Psychiatry 85, 925\u2013935 (2019).","journal-title":"Biol. Psychiatry"},{"key":"1232_CR83","doi-asserted-by":"publisher","first-page":"17099","DOI":"10.1074\/jbc.M113.455899","volume":"288","author":"K Hayakawa","year":"2013","unstructured":"Hayakawa, K. et al. Epigenetic switching by the metabolism-sensing factors in the generation of orexin neurons from mouse embryonic stem cells. J. Biol. Chem. 288, 17099\u201317110 (2013).","journal-title":"J. Biol. Chem."},{"key":"1232_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","volume":"8","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Zhang, Y., Wang, C. & Wang, X. TET (ten-eleven translocation) family proteins: structure, biological functions and applications. Signal Transduct. Target. Ther. 8, 297 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1232_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ebiom.2014.11.005","volume":"2","author":"B Tampe","year":"2015","unstructured":"Tampe, B. et al. Induction of Tet3-dependent epigenetic remodeling by low-dose hydralazine attenuates progression of chronic kidney disease. EBioMedicine 2, 19\u201336 (2015).","journal-title":"EBioMedicine"},{"key":"1232_CR86","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/0008-5472.CAN-22-1029","volume":"83","author":"H Jiang","year":"2023","unstructured":"Jiang, H. et al. Mitochondrial uncoupling induces epigenome remodeling and promotes differentiation in neuroblastoma. Cancer Res. 83, 181\u2013194 (2023).","journal-title":"Cancer Res."},{"key":"1232_CR87","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979\u2013992 e976 (2018).","journal-title":"Cell"},{"key":"1232_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284286","volume":"18","author":"T McFadden","year":"2023","unstructured":"McFadden, T. et al. Controlling hypothalamic DNA methylation at the Pomc promoter does not regulate weight gain during the development of obesity. PLoS ONE 18, e0284286 (2023).","journal-title":"PLoS ONE"},{"key":"1232_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/epigenomes9040038","volume":"9","author":"S Mi","year":"2025","unstructured":"Mi, S., Nakashima, H. & Nakashima, K. Tripartite interaction of epigenetic regulation, brain aging, and neuroinflammation: mechanistic insights and therapeutic implications. Epigenomes 9, 38 (2025).","journal-title":"Epigenomes"},{"key":"1232_CR90","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.it.2025.12.006","volume":"47","author":"J Smolders","year":"2026","unstructured":"Smolders, J., Hsiao, C. C., Huitinga, I. & Hamann, J. Resident T cells in the healthy and multiple sclerosis brain. Trends Immunol. 47, 297\u2013306 (2026).","journal-title":"Trends Immunol."},{"key":"1232_CR91","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nn.3588","volume":"17","author":"JL Huynh","year":"2014","unstructured":"Huynh, J. L. et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat. Neurosci. 17, 121\u2013130 (2014).","journal-title":"Nat. Neurosci."},{"key":"1232_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz198","volume":"43","author":"M Shimada","year":"2020","unstructured":"Shimada, M. et al. Epigenome-wide association study of narcolepsy-affected lateral hypothalamic brains, and overlapping DNA methylation profiles between narcolepsy and multiple sclerosis. Sleep 43, zsz198 (2020).","journal-title":"Sleep"},{"key":"1232_CR93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.neuron.2026.01.019","volume":"114","author":"JJ Ye","year":"2026","unstructured":"Ye, J. J. & Quintana, F. J. Burned by experience: epigenetic inflammatory memory in neurons drives synaptopathy after infection. Neuron 114, 553\u2013555 (2026).","journal-title":"Neuron"},{"key":"1232_CR94","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1232_CR95","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-018-0023-4","volume":"556","author":"AC Wendeln","year":"2018","unstructured":"Wendeln, A. C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature 556, 332\u2013338 (2018).","journal-title":"Nature"},{"key":"1232_CR96","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41586-024-07187-5","volume":"627","author":"HG Lee","year":"2024","unstructured":"Lee, H. G. et al. Disease-associated astrocyte epigenetic memory promotes CNS pathology. Nature 627, 865\u2013872 (2024).","journal-title":"Nature"},{"key":"1232_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115298","volume":"44","author":"SS Drake","year":"2025","unstructured":"Drake, S. S. et al. Cellular rejuvenation protects neurons from inflammation-mediated cell death. Cell Rep. 44, 115298 (2025).","journal-title":"Cell Rep."},{"key":"1232_CR98","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/s41593-025-02041-x","volume":"28","author":"M Belloy","year":"2025","unstructured":"Belloy, M. et al. Toxoplasma gondii infection and chronic IL-1 elevation drive hippocampal DNA double-strand break signaling, leading to cognitive deficits. Nat. Neurosci. 28, 2067\u20132077 (2025).","journal-title":"Nat. Neurosci."},{"key":"1232_CR99","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.neuron.2025.11.006","volume":"114","author":"G Shammas","year":"2026","unstructured":"Shammas, G. et al. Neurons undergo IFN\u03b3-driven persistent epigenetic shifts and synaptopathy in encephalitis. Neuron 114, 622\u2013639.e11 (2026).","journal-title":"Neuron"},{"key":"1232_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0632-2","volume":"11","author":"R Mazzone","year":"2019","unstructured":"Mazzone, R. et al. The emerging role of epigenetics in human autoimmune disorders. Clin. Epigenetics 11, 34 (2019).","journal-title":"Clin. Epigenetics"},{"key":"1232_CR101","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.jaut.2019.102315","volume":"104","author":"P Karagianni","year":"2019","unstructured":"Karagianni, P. & Tzioufas, A. G. Epigenetic perspectives on systemic autoimmune disease. J. Autoimmun. 104, 102315 (2019).","journal-title":"J. Autoimmun."},{"key":"1232_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006953","volume":"4","author":"A Kuroda","year":"2009","unstructured":"Kuroda, A. et al. Insulin gene expression is regulated by DNA methylation. PLoS ONE 4, e6953 (2009).","journal-title":"PLoS ONE"},{"key":"1232_CR103","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00125-010-1967-6","volume":"54","author":"BT Yang","year":"2011","unstructured":"Yang, B. T. et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia 54, 360\u2013367 (2011).","journal-title":"Diabetologia"},{"key":"1232_CR104","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00125-016-3897-4","volume":"59","author":"J Rui","year":"2016","unstructured":"Rui, J. et al. Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice. Diabetologia 59, 1021\u20131029 (2016).","journal-title":"Diabetologia"},{"key":"1232_CR105","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.biopsych.2022.06.027","volume":"92","author":"MH James","year":"2022","unstructured":"James, M. H. & Aston-Jones, G. Orexin reserve: a mechanistic framework for the role of orexins (hypocretins) in addiction. Biol. Psychiatry 92, 836\u2013844 (2022).","journal-title":"Biol. Psychiatry"},{"key":"1232_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47877-2","volume":"15","author":"S Leon","year":"2024","unstructured":"Leon, S. et al. Single cell tracing of Pomc neurons reveals recruitment of \u2018Ghost\u2019 subtypes with atypical identity in a mouse model of obesity. Nat. Commun. 15, 3443 (2024).","journal-title":"Nat. Commun."},{"key":"1232_CR107","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus, N. E. Myasthenia gravis can have consequences for pregnancy and the developing child. Front. Neurol. 11, 554 (2020).","journal-title":"Front. Neurol."},{"key":"1232_CR108","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1474-4422(25)00479-X","volume":"25","author":"DL Rotstein","year":"2026","unstructured":"Rotstein, D. L. et al. Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD. Lancet Neurol. 25, 308\u2013324 (2026).","journal-title":"Lancet Neurol."},{"key":"1232_CR109","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka, K. V. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296, 125\u2013131 (1977).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR110","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl, M. et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630\u2013643 (2009).","journal-title":"Ann. Neurol."},{"key":"1232_CR111","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3389\/fimmu.2020.00991","volume":"11","author":"L Yshii","year":"2020","unstructured":"Yshii, L., Bost, C. & Liblau, R. Immunological bases of paraneoplastic cerebellar degeneration and therapeutic implications. Front. Immunol. 11, 991 (2020).","journal-title":"Front. Immunol."},{"key":"1232_CR112","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0165-2427(99)00058-6","volume":"69","author":"GD Shelton","year":"1999","unstructured":"Shelton, G. D. Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models. Vet. Immunol. Immunopathol. 69, 239\u2013249 (1999).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"1232_CR113","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.180.4088.871","volume":"180","author":"J Patrick","year":"1973","unstructured":"Patrick, J. & Lindstrom, J. Autoimmune response to acetylcholine receptor. Science 180, 871\u2013872 (1973).","journal-title":"Science"},{"key":"1232_CR114","doi-asserted-by":"publisher","first-page":"14781","DOI":"10.1073\/pnas.1617859114","volume":"113","author":"SA Sagan","year":"2016","unstructured":"Sagan, S. A. et al. Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc. Natl Acad. Sci. USA 113, 14781\u201314786 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578109","volume":"380","author":"K Serizawa","year":"2023","unstructured":"Serizawa, K. et al. Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice. J. Neuroimmunol. 380, 578109 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1232_CR116","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41586-024-07079-8","volume":"627","author":"AM Afzali","year":"2024","unstructured":"Afzali, A. M. et al. B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4. Nature 627, 407\u2013415 (2024).","journal-title":"Nature"},{"key":"1232_CR117","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","volume":"139","author":"LM Yshii","year":"2016","unstructured":"Yshii, L. M. et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139, 2923\u20132934 (2016).","journal-title":"Brain"},{"key":"1232_CR118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","volume":"151","author":"NSR Sanderson","year":"2022","unstructured":"Sanderson, N. S. R. Complement and myasthenia gravis. Mol. Immunol. 151, 11\u201318 (2022).","journal-title":"Mol. Immunol."},{"key":"1232_CR119","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus, N. E. Myasthenia gravis. N. Engl. J. Med. 375, 2570\u20132581 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR120","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.cell.2025.03.004","volume":"188","author":"H Li","year":"2025","unstructured":"Li, H. et al. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell 188, 2390\u20132406.e2320 (2025).","journal-title":"Cell"},{"key":"1232_CR121","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/3315","volume":"4","author":"ML Albert","year":"1998","unstructured":"Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321\u20131324 (1998).","journal-title":"Nat. Med."},{"key":"1232_CR122","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12311-022-01446-9","volume":"22","author":"JE Greenlee","year":"2023","unstructured":"Greenlee, J. E. & Brashear, H. R. The discovery of anti-Yo (anti-PCA1) antibody in patients with paraneoplastic cerebellar degeneration: opening a window into autoimmune neurological disease. Cerebellum 22, 531\u2013533 (2023).","journal-title":"Cerebellum"},{"key":"1232_CR123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius, S. et al. Neuromyelitis optica. Nat. Rev. Dis. Primers 6, 85 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1232_CR124","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14740\/jocmr4758","volume":"14","author":"FJ Martinez-Orozco","year":"2022","unstructured":"Martinez-Orozco, F. J. et al. Long-term outcome of a series of patients with narcolepsy type 1 and comorbidity with immunopathological and autoimmune diseases. J. Clin. Med. Res. 14, 309\u2013314 (2022).","journal-title":"J. Clin. Med. Res."},{"key":"1232_CR125","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.26169","volume":"90","author":"L Handunnetthi","year":"2021","unstructured":"Handunnetthi, L. et al. Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease. Ann. Neurol. 90, 455\u2013463 (2021).","journal-title":"Ann. Neurol."},{"key":"1232_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04332-3","volume":"9","author":"K Estrada","year":"2018","unstructured":"Estrada, K. et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat. Commun. 9, 1929 (2018).","journal-title":"Nat. Commun."},{"key":"1232_CR127","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/brain\/awab102","volume":"144","author":"Y Takai","year":"2021","unstructured":"Takai, Y. et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain 144, 2401\u20132415 (2021).","journal-title":"Brain"},{"key":"1232_CR128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski, H. J., Sikorski, P., Coronel, S. I. & Kusner, L. L. Myasthenia gravis: the future is here. J. Clin. Invest. 134, e179742 (2024).","journal-title":"J. Clin. Invest."},{"key":"1232_CR129","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina, A. et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 23, 81\u201394 (2024).","journal-title":"Lancet Neurol."},{"key":"1232_CR130","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s10072-023-07252-3","volume":"45","author":"M Pedrero Prieto","year":"2024","unstructured":"Pedrero Prieto, M., Gorriz Romero, D., Gomez Roch, E., Perez Miralles, F. C. & Casanova Estruch, B. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma. Neurol. Sci. 45, 2199\u20132202 (2024).","journal-title":"Neurol. Sci."},{"key":"1232_CR131","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s12311-024-01727-5","volume":"23","author":"M Dentoni","year":"2024","unstructured":"Dentoni, M. et al. Immune checkpoint inhibitor-related cerebellar toxicity: clinical features and comparison with paraneoplastic cerebellar ataxia. Cerebellum 23, 2308\u20132323 (2024).","journal-title":"Cerebellum"},{"key":"1232_CR132","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41573-024-01026-y","volume":"23","author":"B Becher","year":"2024","unstructured":"Becher, B., Derfuss, T. & Liblau, R. Targeting cytokine networks in neuroinflammatory diseases. Nat. Rev. Drug Discov. 23, 862\u2013879 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1232_CR133","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41583-025-00926-1","volume":"26","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Exploring the complexity of MECP2 function in Rett syndrome. Nat. Rev. Neurosci. 26, 379\u2013398 (2025).","journal-title":"Nat. Rev. Neurosci."},{"key":"1232_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401962","volume":"15","author":"L Li","year":"2024","unstructured":"Li, L. et al. The epigenetic modification of DNA methylation in neurological diseases. Front. Immunol. 15, 1401962 (2024).","journal-title":"Front. Immunol."},{"key":"1232_CR135","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41582-025-01159-7","volume":"22","author":"J Donaldson","year":"2026","unstructured":"Donaldson, J. et al. Huntington disease: somatic expansion, pathobiology and therapeutics. Nat. Rev. Neurol. 22, 5\u201321 (2026).","journal-title":"Nat. Rev. Neurol."},{"key":"1232_CR136","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.3390\/ijms25168921","volume":"25","author":"I Manna","year":"2024","unstructured":"Manna, I., De Benedittis, S. & Porro, D. A comprehensive examination of the role of epigenetic factors in multiple sclerosis. Int. J. Mol. Sci. 25, 8921 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1232_CR137","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/cells13080719","volume":"13","author":"LM De Plano","year":"2024","unstructured":"De Plano, L. M., Saitta, A., Oddo, S. & Caccamo, A. Epigenetic changes in Alzheimer\u2019s disease: DNA methylation and histone modification. Cells 13, 719 (2024).","journal-title":"Cells"},{"key":"1232_CR138","doi-asserted-by":"publisher","first-page":"176641","DOI":"10.1016\/j.ejphar.2024.176641","volume":"975","author":"R Sharma","year":"2024","unstructured":"Sharma, R., Bisht, P., Kesharwani, A., Murti, K. & Kumar, N. Epigenetic modifications in Parkinson\u2019s disease: a critical review. Eur. J. Pharmacol. 975, 176641 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"1232_CR139","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13072-017-0118-4","volume":"10","author":"LC Schenkel","year":"2017","unstructured":"Schenkel, L. C. et al. Identification of epigenetic signature associated with alpha thalassemia\/mental retardation X-linked syndrome. Epigenetics Chromatin 10, 10 (2017).","journal-title":"Epigenetics Chromatin"},{"key":"1232_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1432444","volume":"12","author":"L Xie","year":"2024","unstructured":"Xie, L. et al. Epigenetic insights into fragile X syndrome. Front. Cell Dev. Biol. 12, 1432444 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1232_CR141","doi-asserted-by":"publisher","first-page":"1413248","DOI":"10.3389\/fcell.2024.1413248","volume":"12","author":"CT Roberts","year":"2024","unstructured":"Roberts, C. T., Arezoumand, K. S., Kadar Shahib, A., Davie, J. R. & Rastegar, M. Epigenetics in rare neurological diseases. Front. Cell Dev. Biol. 12, 1413248 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1232_CR142","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41582-022-00693-y","volume":"18","author":"KMJ Van Loo","year":"2022","unstructured":"Van Loo, K. M. J. et al. Epigenetic genes and epilepsy - emerging mechanisms and clinical applications. Nat. Rev. Neurol. 18, 530\u2013543 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1232_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-025-00557-x","volume":"24","author":"H Yang","year":"2025","unstructured":"Yang, H., Sun, W., Li, J. & Zhang, X. Epigenetics factors in schizophrenia: future directions for etiologic and therapeutic study approaches. Ann. Gen. Psychiatry 24, 21 (2025).","journal-title":"Ann. Gen. Psychiatry"},{"key":"1232_CR144","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41392-023-01519-z","volume":"8","author":"M Yuan","year":"2023","unstructured":"Yuan, M. et al. Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential. Signal Transduct. Target. Ther. 8, 309 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1232_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70899-x","volume":"17","author":"TC Thannickal","year":"2026","unstructured":"Thannickal, T. C., Wu, M. F., Cornford, M. E. & Siegel, J. M. Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons. Nat. Commun. 17, 4978 (2026).","journal-title":"Nat. Commun."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01232-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:01:51Z","timestamp":1785412911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01232-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":145,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01232-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"4 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Lausanne holds a patent with M.T. as an inventor on epigenetic treatments for narcolepsy. M.T. has received grant support from Jazz Pharmaceuticals, Axsome Therapeutics, Pharmanovia and NLS Pharmaceutics. R.S.L. has received grant support from Roche, Population Bio and COUR Pharma and has received consulting compensation and speaker honoraria from Biogen, Sanofi-Genzyme, Merck-Serono, Novartis and Hikma. A.V. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}